🇺🇸 FDA
Pipeline program

TAK-385

TAK-385/TB-AK160108

Phase 1 small_molecule completed

Quick answer

TAK-385 for Hormone Treatment-naïve Participants With Prostate Cancer is a Phase 1 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Hormone Treatment-naïve Participants With Prostate Cancer
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials